Substituted biaryl derivatives and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9301929-B2
Application number	US-201013505819-A
Country	US
Kind code	B2
Filing date	Nov 16, 2010
Priority date	Nov 24, 2009
Publication date	Apr 5, 2016
Grant date	Apr 5, 2016

Abstract

The present invention relates to Substituted Biaryl Derivatives, compositions comprising a Substituted Biaryl Derivative, and methods of using the Substituted Biaryl Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.

First claim

What is claimed is:

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein E is:

each occurrence of R 6 is a ring carbon atom substituent and is independently selected from halo, —CF 3 , —OH, alkyl, C 3 -C 7 cycloalkyl and —O—alkyl;
R 15 is alkyl; and
m is 0 or 1.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each occurrence of R 6 is halo.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1.

4. The compound of claim 1 , which is

5. A compound which is

or a pharmaceutically acceptable salt thereof.

6. A composition comprising one or more compounds of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

7. The composition of claim 6 , further comprising one or more additional therapeutic agents, wherein the additional therapeutic agent(s) are selected from an antidiabetic agent and an antiobesity agent.

8. A method for treating diabetes in a patient, the method comprising administering to the patient an effective amount of one or more compounds of claim 1 , or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , further comprising administering to the patient one or more additional therapeutic agents, wherein the additional therapeutic agent(s) are selected from an antidiabetic agent and an antiobesity agent.

10. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

Assignees

• Boyle Craig D
• Lankin Claire M
• Greenlee William J
• Harris Joel M
• Merck Sharp & Dohme

Inventors

• Boyle Craig D
• Lankin Claire M
• Greenlee William J
• Harris Joel M

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• C07D491/08

  Bridged systems · CPC title

• C07D451/02

  containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof · CPC title

• A61K31/00 Primary

  Medicinal preparations containing organic active ingredients · CPC title